Objectives: HIV drug resistance, measured by the genotypic susceptibility score (GSS), has a deleterious effect on the virological outcome of HIV-1-infected patients. However, it is not known if GSS retains any predictive value for CD4 recovery in patients with suppressed viral load.
Introduction
An increasing proportion of persons living with HIV-1 are receiving suppressive ART. 1, 2 Effective ART provides huge benefits in survival, quality of life and health status of people living with HIV-1. 3, 4 Furthermore, a virtual elimination of onward HIV-1 transmission in ideal conditions of treatment access and adherence could be another enormous benefit to our society. 5, 6 For that reason, one of the most cost-effective interventions in HIV care is selecting a specific ART for each HIV-1-infected patient. 7, 8 Virological failure is one of the main concerns for physicians dealing with HIV infection. Failure to suppress viral replication with subsequent salvage ART might result in selection of resistant variants leading exhaustion of treatment options and increased mortality. 9 Mutations in the HIV genome that confer drug resistance are a major reason for virological failure and can affect virological and immunological response to ART. [10] [11] [12] The potential effectiveness of an ART regimen can be quantified by the genotypic susceptibility score (GSS; corresponding to the number of 'active' drugs prescribed) and can be used to predict therapy outcome (viral load suppression).
There is still some controversy as to whether the presence of HIV drug resistance retains a predictive value for CD4 recovery after a treatment switch since some studies have found an association while others did not. [13] [14] [15] However, to our knowledge, no studies have analysed this issue focusing on the period of virological suppression in patients who suppress viral load after treatment switch. Thus, the aim of our study was to evaluate the predictive value of GSS for CD4 recovery in patients who suppress viral load after a treatment switch while on virological failure, who subsequently remain undetectable >1 year without any therapy changes. Our original design included three different timelines: from switch to suppression; from suppression to 1 year of suppression; and from switch to 1 year of suppression.
Methods

Patient selection
We evaluated drug resistance measurements from all HIV-infected patients who enrolled in the British Columbia Drug Treatment Program between 1996 and 2012, previously experienced their first virological failure (>500 copies/mL) while on HAART and switched to a new regimen (N ¼ 1509). Those adults with drug resistance testing within 6 months prior to a change in therapy who subsequently achieved undetectable plasma viral load (<50 copies/mL) within 1 year, whose plasma viral load remained undetectable for up to 2 years on an unchanged regimen and had CD4 data available during the entire follow-up period, were eligible for study (N ¼ 406).
GSS
The GSS was obtained using the Stanford HIVdb genotypic resistance interpretation system. 16 The Stanford algorithm uses five levels of resistance: high-level resistance; intermediate resistance; low-level resistance; potential low-level resistance; and susceptible (i.e. WT). The GSS was used to stratify patients into different categories at the time of virological failure. For each drug prescribed, a GSS value of 1 was assigned if resistance interpretation identified no resistance or potential low-level resistance. A GSS of (a) GSS and CD4þ T cell recovery in HIV-1 patients JAC 0.5 was assigned to prescribed drugs with intermediate resistance or lowlevel resistance, and a value of 0 was assigned to drugs with high-level resistance. The arithmetic sum of the individual scores for the specific drugs prescribed provided the total GSS of that treatment. Patients were grouped corresponding to the number of active drugs prescribed: <2; 2-2.5; and !3. Thus, a value of !3 indicates a fully active regimen, and values of <3 indicate increasingly higher drug resistance and secondarily increasingly less residual antiviral potency of the antiretroviral regimen.
Statistical analyses
CD4 values were collected at three different timepoints: at regimen switch while on virological failure ('switch'); at virological suppression after regimen switch ('suppression'); and after 1 year of virological suppression ('1 year'). Additionally, CD4 values were also collected after 2 years of virological suppression ('2 years'). Patients were grouped into three categories depending on their GSS at switch, corresponding to the number of active drugs prescribed: <2; 2-2.5; and !3. Analysis was further extended up to 2 years of suppression in all patients to explore whether consistent results were generated.
Adjusted and unadjusted linear regression analyses of all baseline characteristics (at switch) related to CD4 recovery were made for three different timelines: from 'switch' to 'suppression' ('switch-suppression'), from 'suppression' to '1 year' ('suppression-1 year') and from 'switch' to '1 year' ('switch-1 year'). Variables that were significant at P < 0.1 in the unadjusted analyses were candidates for inclusion in the multivariable model. The logrank test was used to compare survival curves.
Ethics
This study was approved by the Committee on Human Research and the University of British Columbia/Providence Health Care Research Ethics Board and informed consent was signed by all the participants (H14-00124).
Results
Patient characteristics
GSS was available for 1509 distinct patients with virological failure who switched their regimens ( Figure 1a ). Virological suppression within 1 year after switch was achieved in 1361 of them and 854 remained on the same regimen during the follow-up (up to 2 years of suppression). Of these, those adults with CD4 values available during the follow-up and resistance tests performed no more than 6 months before regimen switch were included in this study (N ¼ 406). GSS was obtained no longer than 6 months before 'switch'. Analyses of CD4 rebound were conducted from 'switch' to 'suppression', from 'suppression' to '1 year' and from 'switch' to '1 year' (Figure 1b) . GSS was !3 in 308 (76%), 2-2.5 in 74 (18%) and <2 in 24 (6%) patients ( Table 1 
Overall CD4 recovery from switch to 1 year by GSS category
The median CD4 increase in the period from switch to 1 year was 140 cells/mm 3 (Q 1 -Q 3 , 60-240). Higher GSS was associated with greater CD4 recovery in 'switch-1 year' in the unadjusted analysis (P ¼ 0.010) ( Table 2 ). Median CD4 was higher in subjects with GSS <2 compared with GSS 2-2.5 and GSS !3 at 'switch'. In the multivariable model, variables associated with CD4 increase in 'switch-1 year' were lower baseline CD4 counts, higher baseline plasma viral load and younger age, while higher GSS was no longer statistically significant (though the effect remained in the expected direction) ( Table 3) . Extending the analysis up to 2 years of suppression in all patients generated consistent results. In addition, use of PI-based regimens or NNRTI-based regimens was not related to a statistically significant CD4 increase from switch to 1 year in the unadjusted analysis (results not shown).
CD4 recovery from switch to suppression by GSS category
The median CD4 increase in the period from 'switch' to 'suppression' was 70 cells/mm 3 (Q 1 -Q 3 , 0-140). Median CD4 counts were Gonzalez-Serna et al.
similar at 'suppression' in subjects with GSS !3 compared with GSS 2-2.5 and GSS <2 (Figure 2a) . Median CD4 increases in the period from switch to suppression were higher in subjects with GSS 2-2.5 and GSS !3 compared with GSS <2 (Table 2) . GSS was strongly associated with a better CD4 recovery in this period in the univariate model (P < 0.001). The main CD4 recovery occurred in this period and the variables associated were baseline CD4 and baseline plasma viral load, maintaining a trend for GSS (Table 3) .
CD4 recovery from suppression to 1 year by GSS category
The median CD4 increase in the period from 'suppression' to '1 year' was 70 cells/mm 3 (Q 1 -Q 3 , 10-140). Median CD4 counts were similar at '1 year' in subjects with GSS !3 compared with GSS 2-2.5 and GSS <2 (Figure 2a) . No differences in median CD4 increases were found in the period from suppression to 1 year or from 1 year to 2 years of virological suppression (Figure 2b) . GSS was not associated with a larger CD4 recovery in this period (P ¼ 0.966) ( Table  2 ). In the multivariable model, only lower baseline CD4 was associated with a larger CD4 increase in the period from suppression to 1 year (Table 3) . Extending the analysis up to 2 years of suppression generated consistent results.
Time to suppression by GSS category
Time to achieve virological suppression from switch was shorter for subjects with GSS <2 than in those with GSS 2-2.5 and GSS !3 (P ¼ 0.022) (Figure 3 ). This shorter time could be associated with GSS and CD4þ T cell recovery in HIV-1 patients JAC the fact that median viral load at switch was lower in subjects with GSS <2 compared with GSS 2-2.5 and GSS !3 [2.2 (IQR 1.7-2.8), 2.4 (IQR 1.7-3.1) and 2.7 (IQR 2.1-3.4) log HIV-1 copies/mL, respectively] (P < 0.001).
Effect of prospective versus retrospective genotypic testing
We wondered if the availability of a recent genotype to the physician before a switch of treatment could be beneficial for the immunological outcome of the patient. Approximately 36% (N ¼ 146) of genotypic testing results were obtained within 30 days of the draw date (the 'prospective' group) and made available to the ordering physician. Amongst those patients, CD4 recovery in the period from switch to suppression was higher in the prospective group compared with those for whom the resistance result were made available to the physician >30 days after the draw date (the 'retrospective' group) (P ¼ 0.026) (Table S1 , available as Supplementary data at JAC Online). In addition, GSS values were slightly higher in the prospective group compared with the retrospective group (P ¼ 0.008). However, time from switch to suppression was not different between both groups (P ¼ 0.808).
Discussion
We have shown in the present study that HIV drug resistance, measured by the GSS, is not related to CD4 recovery during virological suppression (<50 copies/mL) after treatment change. Over Figure 2 . CD4 recovery and increases by GSS category. GSS <2 group started with higher median CD4 counts at 'switch' than GSS 2-2.5 and GSS !3, but achieved similar median CD4 counts at 'suppression' and '1 year'. There was no statistical significance in median CD4 at switch, suppression or 1 year among GSS categories (P ¼ 0.307, P ¼ 0.712 and P ¼ 0.741, at switch, suppression and 1 year, respectively). There was no statistical significance in CD4 change between the first year and second year either (P ¼ 0.272). VL, viral load.
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the entire study period (switch-1 year), we found a greater CD4 recovery in the patients with higher GSS. However, on closer examination this difference in immunological recovery is driven by CD4 increases between the start of a new therapy and virological suppression, and not by improved CD4 recovery during the period of virological suppression itself. Patients with HIV drug resistance who had less than two active drugs on their new regimens had a lower increase in CD4 cell count early after treatment switch, but showed no evidence of a lower CD4 cell increase once they reached viral suppression compared with patients with no HIV drug resistance who received a fully active regimen. This finding suggests that a poor virological response in patients with HIV drug resistance who started on a suboptimal regimen will result in a poorer CD4 response and ultimately higher risk of disease progression. This is an observational study and we specifically included patients who suppressed viral load for more than a year after switch and, therefore, excluded patients with less successful outcome who most likely had lower treatment adherence and GSS. Note that our study focuses on CD4 recovery after virological suppression has been achieved, and excludes those (N ¼ 148; 10% of cohort) who did not suppress their viral loads for 1 year or more after therapy. Previous manuscripts have investigated the role of resistant mutations in those who did not have virological suppression and showed controversial results, but this is the first study focusing on the effect of GSS on CD4 recovery during virological suppression. 13, 15 The patients that received a regimen with a higher GSS had a higher viral load at time of switch and as a result they may have experienced a larger CD4 drop preceding the switch. It could be that a patient with recent CD4 loss has more potential for increase. This may reflect the CD4 redistribution mediated by resolution of the immune activation that had sequestered T cells within lymphoid tissues. In this context, the strength of the regimen, measured by GSS, may play an active role in CD4 recovery. Regimens with more than two active drugs, more important than the detection of HIV-resistant viruses by themselves, or the inclusion of a PI with high genetic barrier drug, are leading this fact. Actually, some studies showed an association between the detection of HIV-resistant viruses and virological suppression and/or CD4 recovery, [17] [18] [19] [20] while others did not. 14, [21] [22] [23] Conversely, all studies using GSS, which may more realistically represent the clinical effectiveness of the regimen, showed some association between number of active drugs and virological suppression and/or CD4 recovery. 13, 15, 24, 25 Several other factors could also explain this controversy. First, some studies found an association, but allowed treatment modifications during the follow-up period, affecting the number of active drugs and thus making results more difficult to interpret. 15 Most of the studies analysed the period from switch to suppression or a year after suppression, which is different from our approach where we made a detailed differentiation in the three time frames ('switch-suppression', 'suppression-1 year' and 'switch-1 year'), where suppression is defined as <50 copies/mL and genotypes were collected <6 months before treatment switch. However, others chose different time frames, established virological suppression >50 copies/mL or genotyped samples, which were collected >6 months before treatment switch. 14, 22 Second, our study has been performed on treatment-experienced patients while most studies have been performed in patients on first-line therapy, who have more antiretroviral options to choose from in earlier stages of the disease, possibly entailing higher GSS. 10, 18 Third, the interpretation of results from genotypic resistance testing from different resistance test systems and algorithms used in different studies could also explain discrepancies between results obtained. 26, 27 Fourth, the number of patients included in our study is higher than in earlier studies, which could also explain Figure 3 . Virological suppression by GSS category. Median CD4 increase in GSS <2 group in 'switch-suppression' was zero and significantly lower than GSS 2-2.5 and GSS !3. However, similar median CD4 increases were achieved by the three groups in 'suppression-1 year' and when the analysis was extended up to '2 years'.
GSS and CD4þ T cell recovery in HIV-1 patients JAC why we found an association between GSS and CD4 recovery in our study whilst others did not. 15, 19 In addition, a higher proportion of patients with fully active regimens and better CD4 recovery in the period from switch to suppression was found in those with genotype results available within 30 days of the blood draw date ('prospective' group). Hence, the availability of a recent genotype to the physician before a switch of treatment could be beneficial for the future immunological outcome of the patients. 11 Finally, we show here that HIV drug resistance, measured by the GSS, is not related to CD4 recovery once virological suppression is established in patients who had switched treatment because of virological failure. However, during the period between treatment switch and virological suppression, the GSS is related to improved CD4 counts in those patients. Our data support performance of a genotypic test before a treatment switch, using the HIV drug resistance data obtained to choose a regimen with more than two active drugs if possible, to improve the immunological outcome of HIV-infected patients after virological failure, but, that once virological suppression has been achieved, GSS has no further role.
